SLC35A2 Double Nickase Plasmid (h): sc-408155-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- SLC35A2 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- SLC35A2 Double Nickase Plasmid (h) and SLC35A2 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting SLC35A2. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SLC35A2 Double Nickase Plasmid (h) | sc-408155-NIC | 20 µg | $410.00 | |||
SLC35A2 Double Nickase Plasmid (h2) | sc-408155-NIC-2 | 20 µg | $410.00 |
SLC35A2 encodes a Golgi-resident UDP-galactose transporter that imports nucleotide sugar substrates into the Golgi lumen to support galactosylation of N- and O-linked glycans and glycolipids. By regulating glycan maturation, SLC35A2 influences protein trafficking, receptor signaling, and cell–cell interactions, with broad effects on membrane and secreted glycoprotein composition. Altered SLC35A2 function disrupts glycosylation homeostasis and has been linked to congenital disorders of glycosylation and neurodevelopmental phenotypes, consistent with the sensitivity of neuronal systems to glycan defects. Research on SLC35A2 also informs pathways governing Golgi glycosyltransferase activity, lectin-mediated quality control, and glycome-dependent modulation of immune and developmental signaling.
SLC35A2 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the SLC35A2 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within SLC35A2. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt SLC35A2 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of SLC35A2-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.